移至標頭移至導覽移至內部移至註腳

研究成果 (12)

排序依據：日期 | 題名

10 | 25 | 50 | 100

上一頁

上一頁

1/2

下一頁

最後一頁

A B D E L P S T 全部

ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
Yang JC, Schuler M, Yamamoto N, O'Byrne KJ, Hirsh V, Mok TSK, Massey D, Zazulina V, Shahidi M, Sequist LV ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
A disintegrin-like and metalloprotease with thrombospondin type 1 motif 9 is a functional tumor suppressor in gastric cancer through inhibiting AKT/mTOR pathway
DU Wan, WANG, Shiyan, LI Xiaoxing, TAO Qian, FANG Jing-yuan Fang, SUNG Joseph Jao-yiu, YU Jun ( 2012 )
The Digestive Disease Week
Other conference paper
A RANDOMIZED PHASE (PH) 2 STUDY WITH EXPLORATORY BIOMARKER ANALYSIS OF FICLATUZUMAB (F) A HUMANIZED HEPATOCYTE GROWTH FACTOR (HGF) INHIBITORY MAB IN COMBINATION WITH GEFITINIB (G) VERSUS G IN ASIAN PATIENTS (PTS) WITH LUNG ADENOCARCINOMA (LA)
Mok TSK, Park K, Geater SL, Agarwal S, Han M, Credi M, McKee K, Kuriyama N, Slichenmyer W, Tan EH ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Mok TSK, Lee JS, Zhang L, Yu C, Thongprasert S, Ladrera GEI, Srimuninnimit V, Truman MI, Klughammer B, Wu Y ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI), FOR FIRST-LINE TREATMENT OF EGFR-MUTANT OR HER2-MUTANT OR -AMPLIFIED LUNG CANCERS
Kris M, Goldberg Z, Janne PA, Kim D, Martins R, Mok TSK, O'Connell J, Ou S, Taylor I, Zhang H ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
EZH2 Silenced Tumor Suppressor miR-218 by Inducing Heterochromatin Formation in Pancreatic Cancer
LI Chi Han Samson, TO Ka Fai, XIAO Zhangang, TONG Hung Man Joanna, ZHU Yinxin, XIA, Tian, LAI Bo San Paul, CHAN Lam Stephen, MARQUEZ V. E., CHEN Yangchao ( 2012 )
2012 American Pancreatic Association and International Association of Pancreatology Joint Meeting
Other conference paper
LUX-LUNG 3: AFATINIB VERSUS CISPLATIN AND PEMETREXED IN JAPANESE PATIENTS WITH ADENOCARCINOMA OF THE LUNG HARBORING AN EGFR MUTATION
Yamamoto N, Schuler M, O'Byrne K, Hirsh V, Mok T, Kato T, Yoshioka H, Okamoto I, Yokoyama A, Massey D, Jones H, Zazulina V, Shahidi M, Sequist L, Yang JCH ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
LUX-LUNG 3: SYMPTOM AND HEALTH-RELATED QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE III STUDY IN 1ST-LINE ADVANCED NSCLC PATIENTS HARBOURING EGFR MUTATIONS
Sequist LV, Schuler M, Yamamoto N, O'Byrne KJ, Hirsh V, Mok TSK, Lungershausen J, Shahidi M, Palmer M, Yang JC ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
PHASE II STUDY OF TWO ERIBULIN REGIMENS IN COMBINATION WITH ERLOTINIB IN PATIENTS (PTS) WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Geater SL, Ianotti N, Thongprasert S, Spira A, Smith D, Lee V, Lim WT, Gopalakrishna P, Reynolds C, Mok TSK ( 2012 )
ANNALS OF ONCOLOGY
Other conference paper
Significance of survivin subcellular localization and splice variants expression in nasopharyngeal carcinoma (NPC): Implication in re-sensitizing cisplatin resistant cell to treatment
WONG Chi Hang, AU Chi Chuen, HUI Wun Chun, CHAN Anthony Tak Cheung ( 2012 )
Other conference paper

10 | 25 | 50 | 100

上一頁

上一頁

1/2

下一頁

最後一頁